

1 **Title:**

2 **The dynamics of oligodendrocyte generation: how distinct is the mouse from the human?**

3

4 **Author information:**

5 David G Gonsalvez<sup>1,3##</sup>, Georgina A Craig<sup>1\*</sup>, Darragh M Walsh<sup>2,4</sup>, Barry D Hughes<sup>2</sup>, Rhiannon J Wood<sup>1</sup>,  
6 Sang Won Yoo, Simon S Murray<sup>1</sup>, Junhua Xiao<sup>1#</sup>

7

8 1. *Dept. Anatomy and Neuroscience, School of Biomedical Sciences, The University of Melbourne,*  
9 *Australia, Parkville, VIC 3010*

10 2. *School of Mathematics and Statistics, The University of Melbourne, Australia, Parkville, VIC 3010*

11 3. *Dept. Anatomy and Developmental Biology, Biomedical Discovery Institute, Monash University,*  
12 *Australia, Clayton, VIC 3800*

13 4. *School of Computing, Insight Centre for Data Analytics, Dublin City University, Ireland*

14

15

16 *Author contributions*

17 *\* Denotes overall equal author contribution. DGG conceived the idea and designed the experiments,*  
18 *performed experiments, analysis, modelling and wrote the paper; GAC, performed the experiments,*  
19 *analysis and critical editing; DMW performed modelling and critical editing; BDH critical editing of*  
20 *the modelling; RJW and SWY performed experiments; SSM critical editing; JX critical editing and*  
21 *supervised the project.*

22

23

24 **#Corresponding author(s):** Correspondence and material requests should be addressed to:

25 1. Dr David G Gonsalvez (email: [david.gonsalvez@monash.edu](mailto:david.gonsalvez@monash.edu)) Department of Anatomy and  
26 Developmental Biology, Monash University, Clayton, Victoria 38000; or

27 2. Dr. Junhua Xiao (email: [xiaoj@unimelb.edu.au](mailto:xiaoj@unimelb.edu.au)), Department of Anatomy and Neuroscience,  
28 The University of Melbourne, Victoria 3010, Australia.

29

30

31

32 **Abstract**

33 Murine oligodendrocyte generation dynamics are considered distinct from those in the  
34 human, with implications for cross-species differences in neural homeostasis, injury response and  
35 ability to functionally adapt circuits through myelin plasticity. We identify that murine  
36 oligodendrocyte precursors do not vary their cell division times *in vivo* and determine how daily  
37 production rates change over a lifespan. We show that murine oligodendrogenesis closely resembles  
38 what is reported for the human.

39

40

41

42

43 **Main**

44 Oligodendroglia comprise a major cellular component of the Central Nervous System (CNS),  
45 and are essential for its proper function. Throughout life, oligodendrocyte precursor cells (OPCs)  
46 generate the new oligodendroglia that are integrated within neural circuitry. This process can be  
47 augmented by neural activity in a form of plasticity known as adaptive myelination<sup>1</sup>. It has been  
48 calculated that homeostatic production rates in adult murine white matter are up to 100-fold greater  
49 than their human counterparts<sup>2</sup>. Such differences in baseline dynamics may have functional  
50 implications in terms of the supply of new oligodendroglia able to partake in myelin plasticity and  
51 raises questions as to whether this form of neural adaptation may have a different degree of  
52 functional relevance across these species.

53 Murine OPCs are reported to be a highly proliferative population that maintains a stable  
54 growth fraction (GF = cells in G1-S-G2-M, but not G0<sup>3</sup>) with up to 98% in the cell cycle<sup>4-9</sup>. To regulate  
55 production OPCs alter their cell cycle length ( $T_c$ ), this can vary from ~36 hours (h) to ~864 h depending  
56 on age and CNS location<sup>4-9</sup>. However, virtually all of the data on murine OPC proliferation dynamics  
57 has been acquired using cumulative labelling with a single thymidine analogue (S-phase tracer)<sup>4-9</sup>.  
58 Although this method is widely used to study proliferation in the CNS, the technique can only  
59 accurately identify *in vivo* cell cycle parameters if several biological assumptions are satisfied<sup>3</sup>.  
60 Unfortunately, parenchymal glial cells violate the key assumptions that underpin these methods  
61 **(Supplementary Figure 1 and methods)**. Therefore, reported values for OPC  $T_c$ , S-phase length ( $T_s$ )  
62 and GF may not appropriately reflect *in vivo* dynamics. Furthermore, modelling that uses these data  
63 may not accurately estimate the rates of murine oligodendrocyte production, and any subsequent  
64 conclusions about cross species developmental differences could be inaccurate.

65 A double S-phase labelling approach incorporating Ki67 immunoreactivity overcomes the  
66 technical limitations of single S-phase tracer cumulative labelling **(Supplementary Figures 2 & 3)**<sup>10</sup>.  
67 Using this approach, we identify that the average OPC  $T_c$  is 35 h  $\pm$  14 h SD and remains remarkably  
68 stable irrespective of age or CNS location **(Figure 1A)**. This range of OPC  $T_c$  values is concordant with  
69 the range of  $T_c$  values reported for rodent OPCs *in vitro*<sup>11</sup>. We also found that the average OPC  $T_s$   
70 was 10 h ( $\pm$  5 h SD) and did not significantly vary across age or location **(Figure 1B)**. In contrast, OPC  
71 GF decreased dramatically with age and was significantly distinct between the corpus callosum and  
72 cortex at all time points assessed **(Figure 1C and Supplementary Figure 3)**. Importantly, the  
73 developmental changes we identified in the murine callosal GF via Ki67 immunoreactivity resemble  
74 what has been reported for the human corpus callosum **(Supplementary Figure 4)**. Moreover, the  
75 GF values we identified are consistent with the fraction of OPCs expressing cell proliferation genes  
76 as determined by single cell RNA sequencing at comparable ages<sup>12</sup>. In the context of demyelinating  
77 injury, we observed no change to OPC  $T_c$  or  $T_s$  **(Figure 1 A and B)** in response to 3 weeks of the  
78 cuprizone-induced CNS demyelination (see methods). That said, cuprizone led to a dramatic increase  
79 in callosal OPC GF **(Figure 1C and Supplementary Figures 3 & 5)**. Collectively, these data provide  
80 evidence that OPCs alter their proliferative behaviour principally through changes in their GF, while  
81 maintaining a consistent  $T_c$  and  $T_s$  *in vivo*.

82 We next used design-based stereology to quantify the developmental changes in tissue  
83 volume **(Supplementary Figure 6)** and absolute numbers of oligodendroglia within an anatomically

84 defined region of the corpus callosum (**Supplementary Figure 7**) and cerebral cortex (**Supplementary**  
85 **Figure 8**). Combining the stereological counts with our cell cycle data, it was possible to identify how  
86 daily OPC production rates change with age. Per unit of volume, callosal and cortical OPC production  
87 rates decline sharply during early postnatal development (**Figure 1D and Supplementary Figure 9A**).  
88 Regional distinctions in how OPC density (**Figure 1E and Supplementary Figure 10F**) and population  
89 GF (**Figure 1C**) change underpin the striking differences in the production rates between the two CNS  
90 regions (**Figure 1D**). We next plotted OPC production against density and this revealed a striking  
91 relationship – the number of new OPCs produced for a given density was consistent regardless of age  
92 or CNS location during normal development (**Figure 1F and Supplementary Figure 9B**). We find that  
93 OPCs maintain an elevated GF when at a higher volumetric density under normal homeostatic  
94 conditions (**Supplementary Figure 9C**). These findings have been validated using data independently  
95 collected by Hughes et al<sup>13</sup> (**data plotted onto Supplementary Figure 9B and C**).

96 In the human corpus callosum the density of proliferating OPCs rapidly declines in early  
97 development and 80% of the total number of mature adult oligodendrocytes are generated by 5-10  
98 years of life<sup>2</sup>. Consistent with these findings, we found that 73% of the total number of mature  
99 callosal oligodendroglia at postnatal day 365 (P365) have been generated by P90 (**Figure 2A**). If we  
100 consider relative differences in lifespan (~90 years for a human<sup>2</sup> and ~900 days for a laboratory  
101 mouse<sup>14, 15</sup>) and the very low rates of adult callosal OPC production (**Figure 1D**), the majority of  
102 callosal oligodendrogenesis is complete within the first 10% of the lifespan in both species. We also  
103 show that the total number of mature oligodendroglia increased until P365 (**Figure 2A and**  
104 **Supplementary Figure 7**). Interestingly, total callosal volume increases to accommodate the rise in  
105 total oligodendrocyte number (**Figure 2B**). We plotted the total number of oligodendroglia against  
106 callosal volume and revealed a very strong positive linear relationship – the callosum maintains a  
107 stable cellular density as it grows in development (**Figure 2C and D**). This means using density  
108 measures alone it may not be possible to accurately capture how populations change within the  
109 oligodendrocyte lineage during development. For example, although we identified a dramatic decline  
110 in the volumetric density of callosal OPCs from P5 to P60 (**Figure 1E and Supplementary Figure 10F**),  
111 there was actually no significant change in their total number over this period (**Figure 2A and**  
112 **Supplementary Figure 7**). The changes in callosal OPC density are not due to an enhanced rate of  
113 differentiation that depletes the total number of OPCs. Instead, high rates of cellular production and  
114 subsequent integration expands the total number of mature callosal oligodendroglia and total  
115 callosal volume (**Figure 2A and B**), and this is what causes the fall in OPC volumetric density (**compare**  
116 **Figures 1E and 2A**). Beyond P60, total callosal OPC number gradually declines with age (**Figure 2A**  
117 **and Supplementary Figure 6**), suggesting over time the rate of proliferation is exceeded by the rate  
118 of differentiation within this self-renewing pool of cells.

119 We next plotted the total number of mature callosal oligodendrocytes against myelin,  
120 assessed by spectral confocal reflectance microscopy (SCoRe), and found a strong positive linear  
121 relationship between the area positive for SCoRe and the number of mature oligodendrocytes in the  
122 corpus callosum (**Figure 2E and Supplementary Figure 11**). To validate this, we plotted the total  
123 number of mature oligodendrocytes against an independent report assessing the proportion of  
124 myelinated axons in the corpus callosum assessed by Transmission Electron Microscopy<sup>16</sup>, and again

125 found a strong positive linear relationship (**Figure 2F**). Our data does not exclude the possibility that  
126 existing cells may re-model the complement of myelin they produce, however it argues that  
127 increasing the total axonal area covered by myelin depends on the addition of new myelinating  
128 oligodendroglia. This finding is consistent with recent reports detailing how myelination occurs in the  
129 adult murine cortex<sup>14, 15</sup>.

130 After 5-10 years of age in the human, the number of newly generated oligodendroglia that  
131 become integrated into the corpus callosum each year accounts for 0.33% of the total mature  
132 oligodendroglia in the tissue<sup>2</sup>. After P90 in the murine corpus callosum, newly generated mature  
133 oligodendroglia expands the existing number of these cells by a rate of 0.44% every 10 days (see  
134 methods for calculation). Accounting for the relative differences in lifespan between these species,  
135 these rates are not strikingly distinct. However, it is important to point out that in our case the 0.44%  
136 rate represents only the addition of new mature oligodendroglia and does not include any cellular  
137 replacement or turnover. We cannot exclude the possibility that existing mature callosal  
138 oligodendroglia may die and subsequently be replaced while their total number expands. However,  
139 our data finds that callosal OPC production rates are extremely low beyond P90 (**Figure 1D**). This,  
140 along with compelling evidence that mature murine oligodendrocytes are remarkably stable<sup>14, 15, 17</sup>,  
141 makes it difficult for us to envisage a situation where a high rate of cellular turnover occurs as part  
142 of normal homeostasis in the murine corpus callosum.

143 We know that programmed cell death eliminates a proportion of the nascent pre-myelinating  
144 oligodendroglia and represents a mechanism that can limit the rate of cellular integration<sup>18</sup>. Using  
145 the daily OPC production rates and stereological counts, we were able to extrapolate total cumulative  
146 production and compare this against the actual change in total oligodendroglial number in corpus  
147 callosum (**Figure 3A**) and cortex (**Figure 3B**). In both regions, cumulative daily OPC production  
148 exceeded the increase in absolute number of all oligodendroglia as determined by stereology  
149 (**Figures 3A & B**). The only way we could account for the excess OPC production was to assign this as  
150 cell death (see methods). To validate these data, we quantified developmental changes in pyknotic  
151 nuclei (**Figure 3C and Supplementary Figure 12**). Combining the pyknotic nuclei counts and data on  
152 the average clearance times for dead cells in the developing CNS<sup>19</sup>, it was possible to estimate total  
153 daily death at different times in the tissue (**Figure 3D**). We found that at all ages our values for excess  
154 production (cell death) were within the estimates for total cell death (**Figure 3D**). In addition to this,  
155 sensitivity analysis was performed using a fixed OPC  $T_c$  value of 35 hours, this generated a cumulative  
156 production curve nearly identical to what we observed when using the measured  $T_c$  values  
157 (**Supplementary Figure 13**). However, a systematic over/underestimation of OPC  $T_c$  by  $\pm$  just one  
158 standard deviation had a profound influence total cumulative production (**Supplementary Figure 13**).

159 There is strong evidence that changes in neural activity can augment the homeostatic rates  
160 of OPC production and new oligodendrocyte integration *in vivo*<sup>1, 20</sup>. Furthermore, blocking the rapid  
161 integration of new oligodendroglia abrogates particular behavioural adaptations that normally occur  
162 in response to altered experience<sup>21</sup>. Our data demonstrate that the volumetric density of OPCs and  
163 their production rates decline in a regionally-specific manner with age (**Figure 1D and E**). These  
164 spatiotemporal changes will influence the probability that an OPC, or newly generated  
165 oligodendrocyte, will be in close proximity to an axon whose activity has been altered. In early

166 postnatal life, the density of OPCs and their production rates are dramatically distinct when  
167 comparing between the corpus callosum and cortex, however these regional differences become  
168 much less pronounced with age (**Figure 1D and E**). These findings may help to explain why the same  
169 level of increased neural activity elicits profound regional distinctions in OPC behaviour in young  
170 mice, but a diminished and more uniform response across the same CNS regions in older animals<sup>1</sup>.

171 Collectively our data provides new fundamental insights on how OPCs function to regulate  
172 cell production *in vivo*. We demonstrate that like other self-renewing cell populations within the CNS,  
173 oligodendrocyte generation dynamics are largely conserved between the mouse and human.

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202


203

204

205

206

207  
208



209  
210 **Figure 1. OPC production rates decline abruptly in early post-natal development.**  
211 **a)** OPC cell cycle length ( $T_c$  – hours) throughout life in the corpus callosum and cortex. In all figures  
212 filled circles represent data from individual mice feed 0.2% cuprizone for 3 weeks and collected at  
213 P77 (3W CPZ). **b)** OPC S-phase length ( $T_s$  – hours) through life in the corpus callosum and cortex. **c)**  
214 OPC Growth Fraction (GF) throughout live in the corpus callosum and cortex. Callosal OPC GF is  
215 dramatically elevated in response to cuprizone-induced demyelination in the corpus callosum (3W  
216 CPZ arrows). The GF was determined using Ki67 immunoreactivity (**Supplementary Figure 3 and 4**).  
217 **d)** Daily OPC production rates in the corpus callosum and cortex during postnatal development. (see  
218 **Supplementary Figure 9a for statistical comparisons between ages**). **e)** Developmental changes in  
219 the volumetric density of OPC in the corpus callosum and the cortex (**for additional statistics see**  
220 **supplementary figure 10f**). **f)** The volumetric density of OPC is positively related to their production

221 rate. The density to production relationships for the cortex (orange line) and corpus callosum (blue  
222 line) were not significantly distinct and followed a global relationship (black line - **see Supplementary**  
223 **Figure 9b for the equations and R<sup>2</sup> values**). Statistics, at each timepoint minimum n=3, 2-way ANOVA  
224 interaction significance indicated by \*\*\* where P < 0.001. In A – E, error bars = SD. In F, the broken  
225 lines indicate 95% confidence intervals.

226

227

228

229

230

231


232

233

234

235

236



237  
238

239 **Figure 2. The majority of mature callosal oligodendroglia are generated within the first 10% of the**  
240 **murine lifespan**

241 **a)** The total number of mature oligodendroglia and OPCs in the corpus callosum over the lifespan.  
242 By P90, 73% of the total number of mature oligodendroglia observed at P365 have been generated.  
243 There is no significant change in total OPC number from P5 to P60. Beyond P60, the total pool of  
244 OPCs is depleted gradually over the course of development (**for additional statistics see**  
245 **Supplementary Figure 7**). **b)** The volume of corpus callosum, bound by the cingulate bundles  
246 laterally, the genu rostrally and selenium caudally, increases with age (**also see supplementary Figure**  
247 **3**). **c)** The total number of oligodendroglia (all Olig2+ cells) has a strong positive correlation with the  
248 total volume in the corpus callosum. Each symbol represents data form an individual animal.  
249 Pearson's  $r = 0.98$ ,  $R^2 = 0.95$  and  $P < 0.0001$  (error = 95% CI). **d)** Age-related changes in cell density



250 within the murine corpus callosum. The density of mature oligodendroglia increases until P60, after  
251 which the increase in number mature callosal OLs occurs with no change in volumetric density (**see**  
252 **additional statistics see Supplementary Figure 8**). **e**) The total number of mature oligodendroglia  
253 (CC1+ Olig2 positive cells) is strongly correlated with the increase in % of callosal area positive for  
254 SCoRe. Each symbol represents data form an individual animal. Pearson's  $r = 0.95$ ,  $R^2 = 0.91$  and  $P <$   
255  $0.0001$  (error = 95% CI). **F**) The number of mature oligodendroglia is strongly correlated with the %  
256 of myelinated axons determined by Sturrock (1980)<sup>16</sup>. Each symbol represents mean values for total  
257 CC1+ Olig2 positive cells where at minimum  $n=3$ /age and mean values of the % of myelinated axons  
258 from Sturrock (1980 – table 1)<sup>16</sup>. Pearson's  $r = 0.99$ ,  $R^2 = 0.97$  and  $P < 0.0001$  (error = 95% CI).

259

260

261

262

263

264

265

266

267


268

269

270

271

272



273

274

**Figure 3: OPCs generate oligodendroglia in excess thought development.**

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

**a)** Cumulative daily production by OPCs in the corpus callosum (teal circles  $\pm$  SD) exceeds the change in total oligodendrocyte number as determined by stereology (bold teal circles  $\pm$  SD). The difference between production and the increase in total oligodendroglial number represents cell death in the system (black broken line). **b)** Cumulative daily production by OPCs in the cortex (pink circles  $\pm$  SD), exceeds the change in total oligodendroglial number determined by stereology (bold pink circles  $\pm$  SD) and cell death (black broken line). **c)** Spatiotemporal distinctions in the density of pyknotic nuclei between the corpus callosum and cortex. **d)** Total pyknotic nuclei counts were used in conjunction with published data on the average time it takes for a dead cell to be cleared from the CNS (140 min)<sup>19</sup> to calculate total daily cell death per mm<sup>3</sup> (see methods). This was compared to the values for daily excess cell production identified in A and B (these values are represented by the solid black bars). The calculated total daily death, using pyknotic nuclei counts and estimated clearance times for dying cells in the cortex, exceeded the level of daily excess OPC production identified for that equivalent day. Statistics, at each timepoint minimum n=3, 2-way ANOVA analysis with multiple comparisons significance: \*, \*\*, \*\*\*, \*\*\*\* = P<0.05, P<0.01, 0.001, and p<0.0001 respectively.

293 **References (Main)**

- 294 1. Gibson, E.M., *et al.* Neuronal activity promotes oligodendrogenesis and adaptive myelination  
295 in the mammalian brain. *Science* **344**, 1252304 (2014).
- 296 2. Yeung, M.S.Y., *et al.* Dynamics of Oligodendrocyte Generation and Myelination in the Human  
297 Brain. *Cell* **159**, 766-774 (2014).
- 298 3. Nowakowski, R.S., Lewin, S.B. & Miller, M.W. Bromodeoxyuridine immunohistochemical  
299 determination of the lengths of the cell cycle and the DNA-synthetic phase for an anatomically  
300 defined population. *J Neurocytol* **18**, 311-318 (1989).
- 301 4. van Heyningen, P., Calver, A.R. & Richardson, W.D. Control of progenitor cell number by  
302 mitogen supply and demand. *Curr Biol* **11**, 232-241 (2001).
- 303 5. Psachoulia, K., Jamen, F., Young, K.M. & Richardson, W.D. Cell cycle dynamics of NG2 cells in  
304 the postnatal and ageing brain. *Neuron Glia Biol* **5**, 57-67 (2009).
- 305 6. Simon, C., Gotz, M. & Dimou, L. Progenitors in the Adult Cerebral Cortex: Cell Cycle Properties  
306 and Regulation by Physiological Stimuli and Injury. *Glia* **59**, 869-881 (2011).
- 307 7. Clarke, L.E., *et al.* Properties and fate of oligodendrocyte progenitor cells in the corpus  
308 callosum, motor cortex, and piriform cortex of the mouse. *J Neurosci* **32**, 8173-8185 (2012).
- 309 8. Young, K.M., *et al.* Oligodendrocyte dynamics in the healthy adult CNS: evidence for myelin  
310 remodeling. *Neuron* **77**, 873-885 (2013).
- 311 9. Rivers, L.E., *et al.* PDGFRA/NG2 glia generate myelinating oligodendrocytes and piriform  
312 projection neurons in adult mice. *Nat Neurosci* **11**, 1392-1401 (2008).
- 313 10. Gonsalvez, D.G., *et al.* Proliferation and cell cycle dynamics in the developing stellate ganglion.  
314 *J Neurosci* **33**, 5969-5979 (2013).
- 315 11. Gao, F.B., Durand, B. & Raff, M. Oligodendrocyte precursor cells count time but not cell d  
316 ivisions before differentiation. *Curr Biol* **7**, 152-155 (1997).
- 317 12. Marques, S., *et al.* Oligodendrocyte heterogeneity in the mouse juvenile and adult central  
318 nervous system. *Science* **352**, 1326-1329 (2016).
- 319 13. Hughes, E.G., Kang, S.H., Fukaya, M. & Bergles, D.E. Oligodendrocyte progenitors balance  
320 growth with self-repulsion to achieve homeostasis in the adult brain. *Nat Neurosci* **16**, 668-  
321 676 (2013).
- 322 14. Hughes, E.G., Orthmann-Murphy, J.L., Langseth, A.J. & Bergles, D.E. Myelin remodeling  
323 through experience-dependent oligodendrogenesis in the adult somatosensory cortex. *Nat*  
324 *Neurosci* **21**, 696-706 (2018).
- 325 15. Hill, R.A., Li, A.M. & Grutzendler, J. Lifelong cortical myelin plasticity and age-related  
326 degeneration in the live mammalian brain. *Nature Neuroscience* **21**, 683-+ (2018).
- 327 16. Sturrock, R.R. Myelination of the mouse corpus callosum. *Neuropathol Appl Neurobiol* **6**, 415-  
328 420 (1980).
- 329 17. Tripathi, R.B., *et al.* Remarkable Stability of Myelinating Oligodendrocytes in Mice. *Cell Rep*  
330 **21**, 316-323 (2017).
- 331 18. Sun, L.O., *et al.* Spatiotemporal Control of CNS Myelination by Oligodendrocyte Programmed  
332 Cell Death through the TFEB-PUMA Axis. *Cell* **175**, 1811-1826 e1821 (2018).
- 333 19. Thomaidou, D., Mione, M.C., Cavanagh, J.F.R. & Parnavelas, J.G. Apoptosis and its relation to  
334 the cell cycle in the developing cerebral cortex. *Journal of Neuroscience* **17**, 1075-1085 (1997).
- 335 20. Mitew, S., *et al.* Pharmacogenetic stimulation of neuronal activity increases myelination in an  
336 axon-specific manner. *Nat Commun* **9**, 306 (2018).
- 337 21. Xiao, L., *et al.* Rapid production of new oligodendrocytes is required in the earliest stages of  
338 motor-skill learning. *Nature Neuroscience* **19**, 1210-1217 (2016).

339

## 340 **Methods and Supplementary Figures**

### 341 **Table of Contents**

342	<b>Methods .....</b>	<b>13</b>
343	<b>Animals:.....</b>	<b>13</b>
344	<b>Tissue collection:.....</b>	<b>13</b>
345	<b>Glia violate the assumptions required for single thymidine-analogue cumulative labelling: .....</b>	<b>13</b>
346	<b>Identifying cell cycle parameters using double S-phase labelling with Ki67:.....</b>	<b>14</b>
347	<b>Immunohistochemistry: .....</b>	<b>16</b>
348	<b>Cuprizone induced demyelination: .....</b>	<b>16</b>
349	<b>Imaging, Spectral Confocal Reflectance Microscopy and image analysis: .....</b>	<b>17</b>
350	<b>Design-based Stereology:.....</b>	<b>17</b>
351	<b>Calculating daily OPC production: .....</b>	<b>17</b>
352	<b>Calculating the % expansion rate for total mature oligodendroglia in the corpus callosum:.....</b>	<b>18</b>
353	<b>Non-linear regression analysis: .....</b>	<b>18</b>
354	<b>Modelling cumulative production and death:.....</b>	<b>19</b>
355	<b>Quantification and validation of cell death:.....</b>	<b>20</b>
356	<b>Sensitivity analysis:.....</b>	<b>21</b>
357	<b>Statistical software: .....</b>	<b>21</b>
358	<b>Supplementary Figures.....</b>	<b>22</b>
359	<b>Supplementary Figure 1. The cumulative labelling method: limitations and assumptions.....</b>	<b>23</b>
360	<b>Supplementary Figure 2: Double S-phase labelling and assessing the GF/LI<sub>0</sub> ratio. ....</b>	<b>25</b>
361	<b>Supplementary Figure 3: Assessing the GF using immunoreactivity for Ki67. ....</b>	<b>27</b>
362	<b>Supplementary Figure 4: GF changes in the corpus callosum of the mouse and human. ....</b>	<b>28</b>
363	<b>Supplementary Figure 5: Cuprizone-induced OPC proliferation and demyelination. ....</b>	<b>30</b>
364	<b>Supplementary Figure 6: Stereology, volume assessments and phenotypic staining.....</b>	<b>32</b>
365	<b>Supplementary Figure 7: Change in total cell numbers in the corpus callosum .....</b>	<b>33</b>
366	<b>Supplementary Figure 8: Change in total cell numbers in the cortex.....</b>	<b>34</b>
367	<b>Supplementary Figure 9: Positive relationship between OPC density, production and GF.....</b>	<b>36</b>
368	<b>Supplementary Figure 10: OL volumetric density in the corpus callosum and cortex .....</b>	<b>37</b>
369	<b>Supplementary Figure 11: Age-related increase in myelin in the corpus callosum .....</b>	<b>38</b>
370	<b>Supplementary Figure 12: Identification and quantification of the % of pyknotic nuclei .....</b>	<b>40</b>
371	<b>Supplementary Figure 13: Sensitivity analysis: systematically varying Tc or GF dramatically alters</b>	
372	<b>cumulative production .....</b>	<b>41</b>
373	<b>Full Reference List: .....</b>	<b>42</b>

374 **Acknowledgements:**.....43  
375

## 376 **Methods**

### 377 **Animals:**

378 C57BL/6 mice were used in all experiments. Mice were housed in specific pathogen-free conditions  
379 at the Melbourne Brain Centre Animal Facility. All animal procedures were approved by The Florey  
380 Institute for Neuroscience and Mental Health Animal Ethics Committee and followed the Australian  
381 Code of Practice for the Care and Use of Animals for Scientific Purposes.

382

### 383 **Tissue collection:**

384 Prior to tissue collection all mice were perfused using phosphate buffered saline (PBS) followed by  
385 4% paraformaldehyde (PFA). Brains were dissected and tissue blocks prepared using the appropriate  
386 coronal brain matrix (Harvard Apparatus). All brains were post-fixed overnight in 4% PFA, then  
387 washed in PBS and transferred to a 30% sucrose solution. Following this, the tissue blocks were  
388 imbedded in OCT and snap-frozen using iso-pentane cooled by dry ice. In all cases blocks were serially  
389 sectioned caudally to rostrally with all sections carefully accounted for. Sections were cut at 25µm.

390

### 391 **Glia violate the assumptions required for single thymidine-analogue cumulative labelling:**

392 Thymidine-analogue cumulative labelling is an assay designed to identify cell cycle parameters of  
393 dividing cells *in vivo*<sup>3</sup>. The method involves continuous delivery of a thymidine analogue (S-phase  
394 tracer) that is incorporated into DNA of cells as they progress through the S-phase of the cell cycle  
395 (**Supplementary Figure 1**). This enables one to measure the rate at which a population of dividing  
396 cells becomes saturated with the S-phase tracer, along with the absolute fraction of cells that  
397 becomes saturated within the population (**Supplementary Figure 1C**). Using this data, it is possible  
398 to determine key cell cycle parameters<sup>3</sup>. However, one caveat to using thymidine analogues is that  
399 once incorporated into the DNA of a cell, the cell is permanently labelled. Therefore, specific criteria  
400 are required in order to exclude any labelled cell that becomes quiescent or moves into G0 over the  
401 labelling period and the method was purpose-designed for use in tissues in which proliferating cells  
402 are anatomically separated from cells that exit the cell cycle or move into G0<sup>3</sup>. For example, in the  
403 dentate gyrus of the hippocampus, it is assumed that any daughter cell that exits the cell cycle and  
404 moves into G0 will leave the anatomically-defined proliferative area, the sub granular zone (SGZ), by  
405 migrating away into the granule cell layer (GCL)<sup>3</sup> (**Supplementary Figure 1B**). The labelled cells that  
406 migrate out of the proliferative zone are purposefully not included in the counts that generate the  
407 cumulative plots (**Supplementary Figure 1B**). Formally, the experimental design for single thymidine-  
408 analogue S-phase cumulative labelling requires that the following assumptions are satisfied<sup>3</sup>:

- 409 1) the cell population is growing at a steady-state, i.e., one-half of the daughter cells leave the  
410 proliferative population and one-half remain in the proliferative population;
- 411 2) no cells within anatomically-defined proliferative zones can exit and re-enter the cell cycle  
412 (move into and out of G0); and
- 413 3) cells within the population divide asynchronously.

414

415 OPCs do not satisfy these assumptions. For parenchymal glia, there is no anatomical  
416 separation between labelled daughter OPCs that exit the cell cycle and move into G0 compared to  
417 cells that remain in cell cycle (**Supplementary Figure 1D & E**). Therefore, it is impossible to segregate  
418 a labelled OPC that becomes quiescent and moves into G0, from cells that are actively dividing when  
419 using a single S-phase tracer alone. This means that the cumulative labelling method cannot  
420 accurately report on the true Growth Fraction within the population. Instead, the population GF will  
421 be overestimated in these circumstances (**Supplementary Figure 1 E–F**). This is reflected in  
422 experimental evidence that near-complete saturation of all OPCs occurs after long enough exposure  
423 to a non-toxic level of S-phase tracer<sup>8</sup>. Furthermore, the rate at which the pool of OPCs becomes  
424 saturated will be influenced by their rates of differentiation and cell death, in addition to the  
425 proliferative behaviour of the OPCs. This means that for any OPC cumulative curve plot, the measured  
426 saturation time is not indicative of cell cycle dynamics alone and cannot be reliably used to accurately  
427 interpret the S-phase length or cell cycle length for OPCs.

428

#### 429 **Identifying cell cycle parameters using double S-phase labelling with Ki67:**

430 To overcome limitations with single S-phase cumulative labelling, we previously devised an approach  
431 that combines an acute double S-phase labelling approach<sup>22</sup> with Ki67 immunoreactivity<sup>10</sup>. This  
432 enables identification of key cell cycle parameters in cell populations where there is no anatomical  
433 separation between actively dividing cells and those in G0<sup>3</sup>. Using this approach, the following  
434 parameters can be identified:

435

436 The S-phase length ( $T_S$ ) – is the time a cell spends in the S-phase of the cell cycle. This is determined  
437 using the double s-phase injection protocol<sup>10, 22</sup>. Mice were injected intraperitoneally, initially with  
438 BrdU (Roche Diagnostics) at 100  $\mu\text{g.g}^{-1}$  body weight and 2 h later with EdU (Invitrogen) at 50  $\mu\text{g.g}^{-1}$   
439 body weight. Thirty minutes after the injection of EdU, mice were sacrificed by lethal injection of  
440 pentobarbitone and perfused. Identification of the length of s-phase can be determined using the  
441 following relationship:

442

443 1)  $T_S = \frac{\text{injection interval (hours)} \times \text{cells that left S-phase over the interval}}{\text{Cells that remained in S-phase over the interval}}$ ; or

444

445 2)  $T_S = \frac{\text{injection interval (hours)} \times \text{cells labelled by 1}^{\text{st}} \text{ tracer only}}{\text{Cells labelled by the 2}^{\text{nd}} \text{ tracer}}$ ; or

446

447 3)  $T_S = \frac{2 \times \text{OPCs+ve for BrdUonly (lack EdU)}}{\text{OPCs+ve for EdU}}$

448

449 The 2-hour interval between injections of BrdU and EdU was selected based on previous  
450 literature assessing cell cycle dynamics for neuroblasts and glial cells in neural tissues<sup>10, 22</sup>. This  
451 technique requires accurate identification of the proportion of cells that left S-phase over the  
452 injection interval<sup>22</sup>. The order of injection BrdU first, followed second by EdU is very important. A  
453 carbon alkyne is engineered into the EdU and the azide-N<sub>3</sub>-fluorophore used to identify the EdU is

454 attached via a Copper-catalyzed azide-alkyne cycloaddition. This means it is not possible for the EdU  
455 fluorophore to cross-react or falsely detect the BrdU in the system (**Supplementary Figure 2**). The  
456 double S-phase labelling protocol requires that a measurable number of cells pass through S-phase  
457 over the injection interval<sup>22</sup>. Unfortunately, in the cortex at P90 and P365, too few cells passed  
458 through S-phase over the injection interval to reliably report on the S-phase length, so cortical  
459 assessments were performed until P60. We were able to obtain S-phase lengths for animals at P365  
460 only in the corpus callosum. However, it must be noted that we observed very few OPCs positive for  
461 BrdU only at P365.

462  
463 The Instantaneous Labelling Index ( $Li_0$ ) – is the fraction of cells actively in S-phase at any instant. The  
464 double s-phase labelling technique used to identify  $T_s$  enables identification of the fraction of OPCs  
465 labelled by EdU (a 30min pulse) and BrdU (a 150 min pulse) in each animal. The  $Li_0$  is the y-intercept  
466 from a least of squares linear equation derived by passing a line through measured fractions of  
467 labelled OPCs at 30 min and 150 min of exposure time<sup>10, 22</sup> (**Supplementary figure 2**).

468  
469 The Growth Fraction ( $GF$ ) – is the fraction of cells within a population that are actively in the cell cycle,  
470 or all cells excluding those that are in  $G_0$ <sup>3</sup>. This was determined using immunofluorescence for Ki67  
471 and PDGFR $\alpha$  (**Supplementary Figure 3**)<sup>10</sup>. Ki67 expression discriminates cells in G1-S-G2-M from cells  
472 in  $G_0$ <sup>10, 23, 24</sup>. The Ki67 protein has a short half-life (60-90min) and its levels change in different phases  
473 of the cell cycle<sup>24-26</sup>. Although Ki67 is routinely used as a binary marker of proliferating cells, there is  
474 evidence that under some *in vitro* conditions a lag in the onset of Ki67 expression may occur early in  
475  $G_1$ <sup>24-26</sup>. While this lag is not long (1 -2 hours) and is only observed when cells have been deprived of  
476 growth factors then re-introduced to mitogens, or when cells are maintained in  $G_0$  by experimental  
477 manipulation of mitotic checkpoints and then returned into the cell cycle, nevertheless it is possible  
478 that a lag in onset of Ki67 expression may occur during early  $G_1$  for *in vivo* OPCs that have been  
479 quiescent then re-enter the cell cycle<sup>24-26</sup>. To test if OPCs *in vivo* may have a significant lag in the  
480 onset of Ki67 expression we plotted the  $GF/Li_0$  (The fraction of dividing cells, identified by Ki67 /  
481 fraction of cells in S-phase identified by double S-phase labelling). If quiescent OPCs that move from  
482  $G_0$  to  $G_1$  have some significant lag in the onset of Ki67 expression, this must lead to a decrease in the  
483  $GF/Li_0$  fraction as OPCs become less proliferative with age. We found no significant change in the  
484  $GF/Li_0$  fraction across age, location or in response to cuprizone (**Supplementary Figure 2D**). Our data  
485 does not support a hypothesis that an extended lag in the onset of Ki67 occurs during  $G_1$  phase of  
486 the cell cycle of OPCs *in vivo*. High resolution images were assessed in all cases for determining the  
487  $GF$ . PDGFR $\alpha$ + pericytes were always excluded from counts, this was done based on their morphology  
488 and proximity to parenchymal blood vessels<sup>27</sup> (**Supplementary Figure 3B**).

489  
490 The cell cycle length ( $T_c$ ) – is the time taken for a cell to complete cell division, or the time taken to  
491 pass through  $G_1$ , S,  $G_2$  and M. This can be determined using the formula<sup>3</sup>:

492

493

$$T_c = \frac{T_s \times GF}{Li_0}$$

494

495 One benefit of our approach is that all of the cell cycle parameters  $T_s$ ,  $Ll_0$ ,  $GF$  and  $T_c$  can be  
496 determined for individual animals, rather than relying on pooled data. This is not possible using single  
497 S-phase cumulative labelling, where pooled averages from multiple animals are required to  
498 determine each single parameter at a given age.

499

### 500 **Immunohistochemistry:**

501 We devised a sampling strategy to obtain cell cycle data and stereological counts from the same  
502 individual, with sections processed in one of 4 ways:

- 503 1) Sections were processed for PDGFR $\alpha$  immunofluorescence (Table 1) before being treated  
504 with 2N HCl for 30 min at room temperature and then 0.1 M sodium tetraborate. They were  
505 then processed for BrdU immunofluorescence and finally reacted for EdU as per the  
506 manufacturer's instructions for the Click-iT EdU Alexa Fluor 647 imaging kit (**Supplementary  
507 Figure 2**);
- 508 2) Sections were subjected to antigen retrieval (10 min at 90°C in 0.01 M citrate buffer, pH 6.0),  
509 reveal then processed for Ki67 and PDGFR $\alpha$  immunofluorescence (Table 1) <sup>27</sup>  
510 (**Supplementary Figure 3 and 5**);
- 511 3) Sections used for stereology counts were processed for Olig2, PDGFR $\alpha$  and CC1  
512 immunoreactivity (Table 1), this enabled identification of phenotypically distinct cells within  
513 the oligodendrocyte lineage (**Supplementary Figure 6**); or
- 514 4) Sections were processed for IBA-1 immunoreactivity (table 1) in antisera free of any  
515 detergents that enabled combined SCoRe assessments in cuprizone fed mice<sup>28</sup>  
516 (**Supplementary Figure 5**).

517

<i>Antibodies and reagents</i>	<i>Source</i>	<i>Concentration</i>	<i>Reference</i>
Goat anti Platelet derived growth factor alpha (PDGFR $\alpha$ )	AF1062, R&D Systems	1:200	Fletcher et al (2018)
Mouse anti-APC (AB-) MAB CC1	OP80, CalBioChem	1:200	as above
Rabbit anti Olig2 - Rabbit	AB9610, Millipore	1:200	as above
Rat anti 5-Bromo-2'-deoxyuridine (BRdU) - Rat	Abcam (ab6326)	1:40	Gonsalvez et al (2013)
Rabbit anti Ki76 -Rabbit	RM-9160, Thermo	1:100	as above
5-Ethyl-2-deoxyuridine 647 Click reaction kit	Life Technologies	as per kit	as above
Bisbenzamide - Hoechst 33342	Sigma	1 $\mu$ g /ml	as above
Goat anti IBA-1	Abcam (ab5067)	1:200	

518

### 519 **Cuprizone induced demyelination:**

520 8-week-old mice were fed 0.2% cuprizone in normal chow (Teklad Custom Research Diets)<sup>28</sup>. After 3  
521 weeks of dietary cuprizone supplementation mice were sacrificed and tissue processed as described  
522 previously. Animals were injected and all tissue was processed as previously described. Confirmation  
523 that cuprizone had elicited inflammation and demyelination was determined using SCoRe imaging  
524 and immunofluorescence for IBA-1+ microglia (**Supplementary Figure 5**)<sup>28</sup>.

525



526 **Imaging, Spectral Confocal Reflectance Microscopy and image analysis:**

527 All images were captured on either a Zeiss LSM 880 (Airyscan), Zeiss LSM780 confocal microscope,  
528 or Zeiss Axio M2 with apotome. Spectral Confocal Reflectance Microscopy (SCoRe) was performed  
529 using either the Zeiss LSM 880 or LSM780 microscopes. Both microscopes were fitted with a water  
530 immersion objective (Zeiss W Plan-Apochromat 40 /1.0 NA DIC) using 458, 561, and 633-nm laser  
531 wavelengths passed through the Acousto-Optical Tunable Filters (AOTF) 488–640 filter/splitter and  
532 a 20/80 partially reflective mirror. The reflected light was collected using three photodetectors set  
533 to collect light through narrow bands defined by prism and mirror sliders, cantered around the laser  
534 wavelengths 488, 561, and 633 nm. The channels from each photodetector were then overlaid as  
535 one composite image for analysis. In all cases SCoRe images were pseudo coloured in cyan. All images  
536 were acquired using the same process. The tile scans captured for each section were taken in a single  
537 z-plane at a minimum at a depth of 3 micron from the surface. Only compact myelin reflects light to  
538 produce a positive signal. Positive pixels were identified on a minimum threshold cut-off using the  
539 threshold function in Fiji. Measurements of the resulting area were divided by the total area of the  
540 ROI<sup>28, 29</sup>. A minimum of n=3 was captured for each age.

541

542 **Design-based Stereology:**

543 The anatomical structures of the cingulate bundles laterally, and the rostral and caudal midline  
544 unions of the corpus callosum were used to define the anatomical boundaries of the cortical and  
545 callosal tissue sampled (**Supplementary Figure 6**). To ensure systematic random sampling, brains  
546 were serially sectioned (25µm thick). This approach meant any developmental changes in the tissue  
547 volumes bound by these anatomical landmarks could be determined (**Supplementary figure 6**). All  
548 nucleated cells in the corpus callosum and cortex were counted using the optical fractionator method  
549 with Stereo Investigator version 11.01.02; (MBF Bioscience). The total section thickness was  
550 measured at every single counting site to maximise the accuracy in volume estimates. To identify the  
551 total number of all oligodendroglia, OPCs, oligodendrocytes and non-oligodendrocytes in each  
552 animal, sections were also processed for multi-label immunofluorescence (**Supplementary Figure 6**).  
553 The grid frame and counting window sampling protocol used ensured a Gundersen M0 Coefficient of  
554 Error (M0 CE) of <0.05, significantly less than the commonly accepted M0 CE variance value of 0.1.  
555 Total cell numbers for the corpus callosum and cortex (**Supplementary Figure 7** and **Supplementary**  
556 **8** respectively). Total cell density per mm<sup>3</sup> for the corpus callosum and cortex (**Supplementary Figure**  
557 **11**)

558

559 **Calculating daily OPC production:**

560 Daily production was calculated by identifying the total numbers of dividing OPCs. This was achieved  
561 by multiplying the total number of OPCs identified through stereology (**Supplementary Figure 7-8**),  
562 by the Growth Fraction identified by Ki67 immunoreactivity (**Figure 1C**). It was then possible to  
563 calculate daily cell production in the following way:

564

565 
$$\text{Daily production} = \frac{\text{number of dividing OPCs} \times 24 (h)}{T_c (h)}$$

566

567 The stereological approach included measuring the total tissue volume (**Supplementary Figure 6**). It  
568 was therefore possible to convert total daily production to a volumetric density:

569

$$570 \text{ Daily production per mm}^3 = \frac{\text{number of dividing OPCs per mm}^3 \times 24 \text{ (h)}}{T_c \text{ (h)}}$$

571

572 For the corpus callosum, we determined cell cycle parameters and stereological data at the  
573 following data points: P5, P7, P15, P60 and P90 and P365. To determine the number of OPCs, linear  
574 interpolation between the measured mean values of the GF and  $T_c$  was used, enabling us to model  
575 how production changed between the measured data points.

576

### 577 **Calculating the % expansion rate for total mature oligodendroglia in the corpus callosum:**

578 To estimate the % expansion rate for mature oligodendroglia in the murine corpus callosum that  
579 occurs after P90, we make the following assumptions:

- 580 1) That beyond P365 there is no significant increase in total mature callosal oligodendroglia; &
- 581 2) The average murine lifespan is 900 days

582

583 To determine the % rate of expansion we performed a simple calculation:

584

$$585 \text{ mature OLs gained per day after P90} = \frac{\text{total number of mature OLs gained after P90}}{\text{total number of days after P90}}$$

586

$$587 \text{ 134 mature OLs gained per day after P90} = \frac{108482}{810}$$

588

$$589 \text{ \% increase in mature OLs per day} = \frac{134 \text{ mature OLs gained per day}}{299319 \text{ mature OLs at P90}}$$

590

$$591 \text{ \% increase in mature OLs per day} = 0.044\% (.00044 * 100)$$

592

$$593 \text{ \% increase in mature OLs every 10 days} = 0.44\%$$

594

### 595 **Non-linear regression analysis:**

596 We plotted cortical and callosal OPC volumetric density against daily production (**Figure 1E**). This did  
597 not follow a linear relationship, but we found that the data fitted the Gompertz non-linear regression  
598 model:

$$599 Y = Y_M \times \left( \frac{Y_0}{Y_M} \right)^{(e^{-K \times X})}$$

600

601 where  $X$  is the OPC density per  $\text{mm}^3$  and  $Y$  is the daily production per  $\text{mm}^3$ . Two of the three  
602 parameters  $Y_0$ ,  $Y_M$  and  $K$  have simple interpretations:  $Y_M$  is the extrapolated production rate at  
603 mathematically infinite OPC density and serves as an estimate of the production rate at the highest  
604 achievable OPC density, while  $K$  (its units being the inverse of those of  $X$ ) controls the rate of

605 variation of production with OPC density. The parameter  $Y_0$  can be interpreted mathematically, but  
606 only with some diffidence, as the production rate extrapolated to zero OPC density. The fitting was  
607 performed with GraphPad Prism 8 for MacOS (see [www.graphpad.com/guides/prism/8/curve-](http://www.graphpad.com/guides/prism/8/curve-fitting/reg_gompertz-growth.htm)  
608 [fitting/reg\\_gompertz-growth.htm](http://www.graphpad.com/guides/prism/8/curve-fitting/reg_gompertz-growth.htm), accessed June 19, 2019, but note that their interpretation of  $1/K$   
609 as the  $X$  value of the inflection point is not correct, the true inflection point being located at  
610  $\ln\{\ln[Y_M/Y_0]\}/K$ ). The fit was confirmed using the NonlinearModelFit function in Mathematica  
611 Version 11 (Wolfram Research), with the Prism 8 fitting parameters rounded to two significant figures  
612 as initial values in the parameter search and all parameters constrained to be positive. The values for  
613  $Y_M$ ,  $Y_0$ ,  $K$  and the  $R^2$  for each equation are given in **(Supplementary Figure 9 B)**.

614

615 To identify if OPC volumetric density was correlated with their probability for division we plotted OPC  
616 density against OPC GF **(Supplementary Figure 9 C)**. We fit the data using the Padé (1,1) non-linear  
617 regression model in GraphPad Prism 8:

618 
$$y = \frac{(A_0 + A_1 \times x)}{(1 + B_1 \times x)}$$

619

620 A comparison of fits with the null hypothesis that one curve fits all data points was not possible to  
621 reject  $P = 0.3715$ . This data indicates that irrespective of age or location, OPCs GF was positively  
622 correlated to their volumetric density under normal homeostatic conditions *in vivo* **(Supplementary**  
623 **Figure 9C)**.

624

### 625 **Modelling cumulative production and death:**

626 Cumulative production was identified by cumulatively adding daily production values to the initial  
627 number of total OLs (All Olig2+ cells) determined by stereology at P5. Cumulative production  
628 exceeded the increase in total OL number determined by stereology in both the corpus callosum and  
629 cortex **(Figure 3 A–B)**. The differences between the cumulative curve, and the measured number of  
630 OPCs in the tissue represents the excess cell production **(Figure 3 A–B)**. The only way that we could  
631 account for the excess OPC production was to assign this as the cell death in the system. This is based  
632 on the following assumptions:

- 633 1) PDGFR $\alpha$ + Olig2 + OPCs only produce cells that contribute to the oligodendrocyte lineage<sup>8</sup>;
- 634 2) Within the large anatomically-defined volumes of cortex and corpus callosum assessed, net  
635 OPC migration = 0. OPCs are highly mobile and although some can move a considerable  
636 distance (up to 100 $\mu$ m in 2 weeks), there is no directional bias to this movement<sup>13</sup>. Since the  
637 net displacement of any cell is typically no more than 50 $\mu$ m with no direction bias and OPCs,  
638 maintain an evenly-spaced grid-like pattern despite developmental changes in their overall  
639 density and we assume that any OPCs that migrate into the ROI volume will be offset by an  
640 equal number of OPCs that migrate out<sup>13</sup>.
- 641 3) The total number of Olig2+ cells within the cortex and corpus callosum cannot be increased  
642 by the differentiation of cells that are not within the oligodendroglia lineage, cells that do not  
643 express the pan oligodendrocyte marker Olig2 or equivalents such as Sox10.

644

645 We intentionally sampled the septal component of the corpus callosum bound by the cingulate  
646 bundles laterally. In addition to ensuring anatomical landmarks that persist through development,  
647 there is good evidence that Sub Ependymal stem cell derived OPCs do not populate this region of the  
648 corpus callosum<sup>30</sup>. However, it is possible that a very small pool of SEZ- derived OPCs may be included  
649 as part of our analysis. SEZ-derived OPCs express PDGFR $\alpha$  and Olig2<sup>30</sup>, satisfying the assumption that  
650 the total pool of oligodendroglia can only be increased by cells committed to the oligodendrocyte  
651 lineage.

652

### 653 **Quantification and validation of cell death:**

654 To estimate the levels of cell death in the corpus callosum and cortex, we adopted a published  
655 protocol to identify pyknotic nuclei using Hoechst 33342 labelling<sup>31</sup>. For every age assessed, n = 3–4  
656 and analysis was performed on high-resolution confocal images (**Supplementary Figure 11**). After  
657 P60, pyknotic nuclei were rare and it was not feasible to quantify these cells. In addition, the pyknotic  
658 nuclei counts were performed on individuals that were also subject to stereological analysis. This  
659 made it possible to identify the volumetric density of pyknotic nuclei at each age assessed (**Figure**  
660 **3C**). To estimate total cell death in 24 hours per mm<sup>3</sup> (**Figure 3D**), we used published data that cells  
661 in an irreversible stage of cell death remain in the tissue for ~140 minutes prior to phagocytic  
662 clearance in the CNS<sup>19, 32, 33</sup>. Assuming that cells die at random (i.e they are not all symmetrically  
663 dying at a single instance) it was possible to use our pyknotic nuclei density counts plus a cellular  
664 clearance time of 140 minutes<sup>19</sup> to estimate daily cell death within a mm<sup>3</sup> of either callosal or cortical  
665 parenchyma. To do this we used the following:

666

$$667 \text{ Daily death per mm}^3 = \frac{\text{Pyknotic nuclei per mm}^3 \times \text{number of minutes in a day}}{\text{average clearance time}}$$

668

669 where

- 670 • number of minutes in a day = 60 min x 24 = 1440;
- 671 • average clearance time = 140 min.

672

673 Despite performing multilabel immunofluorescence (**Supplementary Figure 11**), it was not possible  
674 to assign a fraction of pyknotic nuclei specifically to the OL lineage. Therefore, the cell death values  
675 represent total cell death that occurs via pyknosis. Death in the OL lineage will account for some  
676 proportion of this total death. The % of pyknotic nuclei we identified was consistent with a previous  
677 assessment performed in the Optic nerve (**Supplementary Figure 11**), as well as with identified  
678 densities of activated caspase 3 cells in the cortex at similar ages<sup>34, 35</sup>. Assessing pyknosis is unlikely  
679 to capture 100% of all cell death. Cells may die by other means (eg. phagoptosis) and this would not  
680 be captured in our counts. It is likely that total cell death *in vivo* may exceed our estimates  
681 determined by counting pyknotic nuclei and modelling clearance times. Nevertheless, our data  
682 indicates that cell death within the OL lineage must account for a considerable proportion of the  
683 overall homeostatic levels of ongoing cell death that occurs in both cortical and callosal tissues *in*  
684 *vivo*.

685 **Sensitivity analysis:**

686 Our data revealed that OPCs have an average Tc of 35 h (**Figure 1A**). To provide additional validation,  
687 we modelled cumulative production in the corpus callosum as described previously except using a  
688 fixed OPC Tc of 35 hours. (**Supplementary Figure 13**). This generated a cumulative plot that was very  
689 similar to what is generated when we use measured values of Tc. We next asked the question; how  
690 sensitive is the system to a systematic over- or under-estimation of Tc or GF? To address this we  
691 systematically over- or underestimated Tc or GF and generated cumulative plots (**Supplementary**  
692 **Figure 13**). A systematic error in measuring either Tc or GF would lead to dramatic alterations in total  
693 cumulative production and such changes would be inconsistent with the levels of cell death we  
694 observed (**Figure 3 and Supplementary Figure 11**). Additionally, this analysis showed that the system  
695 is most sensitive to systematic changes in Tc: altering Tc by just one standard deviation of the  
696 measured value at each age had a profound impact on total cell production.

697

698 **Statistical software:**

699 All statistical tests performed are described in the relevant figure legends. We used GraphPad Prism  
700 version 8 for MacOS, GraphPad Software, San Diego, California USA, and where necessary, we  
701 validated non-linear regression modelling using Mathematica Version 11 (Wolfram Research).

702

703

704

705

706


707

708




709

710

711



714 **Supplementary Figure 1. The cumulative labelling method: limitations and assumptions.**  
715 **A)** Illustration of proliferating cells within the dentate gyrus of the hippocampus that incorporate the  
716 S-phase tracer into their DNA (labelled green) over time (t1, t2 & t3). Postmitotic cells retain the S-  
717 phase tracer, however they leave the anatomically defined proliferative subgranular zone (SGZ) and  
718 mitigrate into the granule cell layer (GCL). **B)** The cumulative labelling method assumes that as soon  
719 as a cell enters G0 it migrates out of the anatomically-defined proliferative zone<sup>3</sup>, in this case the  
720 SGZ. The method also this assumes that no cells within the SGZ have the capacity to exit and re-enter  
721 the cell cycle, meaning the system is in a steady-state of growth<sup>3</sup>. **C)** Example of a cumulative labelling  
722 plot. When the biological assumptions are satisfied, plotting and determining the rate at which a  
723 population of cells becomes saturated makes it possible to determine key cell cycle parameters<sup>3</sup>:  
724 The cell cycle length ( $T_c$ ), the growth fraction ( $GF$ ), the labelling index ( $LI_0$ ), and the S-phase length  
725 ( $T_s$ ). The labels t1, t2 & t3 on the horizontal axis correspond to the same labels in the illustrations  
726 given in A). **D)** Image to illustrate that OPCs can divide, transition between dividing and non-dividing  
727 (enter and exit G0), differentiate, or die within the tissue. **E)** When an S-phase tracer is continuously  
728 delivered in this instance (t1, t2 & t3), dividing OPCs will incorporate it during S-phase (green).  
729 However, thymidine analogue S-phase tracers permanently label the daughters and there is no  
730 means to separate daughter OPCs that move in to G0 (labelled G0) from those activity dividing the  
731 system. Violation of this assumption leads to an overestimation of the  $GF$ <sup>3</sup>. To overcome this barrier,  
732 we used Ki67 to identify actively dividing cells<sup>10, 23</sup> (**Supplementary Figure 3**).







734 **Supplementary Figure 2: Double S-phase labelling and assessing the GF/LI<sub>0</sub> ratio.**

735 **a)** Schematic of the double S-phase labelling method used. **b)** Illustration of double S-phase labelling  
736 at P5 in the corpus callosum. Arrow heads identify OPCs positive for PDGFR $\alpha$ , BrdU and EdU,  
737 demonstrating that these cells were in S-phase for the duration of the injection interval. Star  
738 identifies an OPC positive for PDGFR $\alpha$  and BrdU only, demonstrating a cell that transitioned through  
739 the S-phase prior to the injection of the second tracer (EdU). Scale bars in the lower and upper images  
740 indicate 200  $\mu$ m and 10  $\mu$ m respectively. **c)** The Instantaneous Labelling Index (LI<sub>0</sub>), is the fraction of  
741 cells in S-phase at any instant. This is significantly distinct between the corpus callosum and cortex  
742 and is elevated in response to 3 weeks of cuprizone demyelination. **d)** The ratio of GF/LI<sub>0</sub> ratio does  
743 not significantly change across region, either with age, or in response to cuprizone demyelination.  
744 For all data; n=3–4 per data point. Statistics: 2-way ANOVA interaction (black line) and multiple  
745 comparisons (black connectors and coloured lines). Significance is indicated: ns = no significance and  
746 the p values: p<0.05, p<0.01, 0.001, and p<0.0001 represented by \*, \*\*, \*\*\*, \*\*\*\* respectively. Error  
747 Bars represent  $\pm$  SD.

748

749




751 **Supplementary Figure 3: Assessing the GF using immunoreactivity for Ki67.**

752 **a)** The fraction of Ki67+ actively dividing OPCs decreases with age, however this is dramatically  
753 elevated in response to 3 weeks of cuprizone mediated demyelination (P77 CPZ). Arrow heads  
754 indicate actively dividing OPCs positive for both PDGFR $\alpha$  and Ki67. Stars denote OPCs positive for  
755 PDGFR $\alpha$  but not expressing Ki67. Bars: large image and small image 200  $\mu$ m and 20  $\mu$ m respectively.

756 **b)** Image illustrating that in young adult mice (P60), few OPCs are positive for Ki67 under normal  
757 homeostasis. The enlarged square was selected due to the presence of blood vessels: it is possible to  
758 discriminate the morphological differences between PDGFR $\alpha$ + OPCs (arrowheads and stars), and  
759 pericytes found lining blood vessels (open arrows)<sup>27</sup>. Care was taken to ensure PDGFR $\alpha$  positive  
760 pericytes were excluded from all analysis. Bars show 200  $\mu$ m (large image) and 20  $\mu$ m (small image).

761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776

⊕ murine corpus callosum  
 - - human corpus callosum extrapolated from Yeung et al., 2014



777




778

**Supplementary Figure 4: GF changes in the corpus callosum of the mouse and human.**





779

Representation of total oligodendroglia that are positive for Ki67 in the mouse (each open circle represents data from an individual animal where n=3-4/age. The total number of OPCs (PDGFR $\alpha$ +Ki67+cells) represents a sub population of the total number of all oligodendroglia in the tissue. The data in this figure is distinct from the data represented in Figure 2C, in that here we express the Ki67 fraction in terms of all oligodendroglia as determined via stereology. This exercise is simply to compare the murine data we collected, against human data from Yeung et al., (2014) where the GF was represented as the fraction of all oligodendroglia that express Ki67. The dashed black line in this figure was generated by joining a straight line between values for individual subjects extrapolated from the article by Yeung et al 2014 (see Figure S4 G). We find that developmental changes in OPC GF occur in a similar way for both murine and human corpus callosum.

789



791 **Supplementary Figure 5: Cuprizone-induced OPC proliferation and demyelination.**  
792 **a)** Ki67 staining in the corpus callosum is dramatically elevated in response to cuprizone  
793 demyelination. **b)** BrdU and EdU labelling within OPCs in the corpus callosum in response to  
794 cuprizone demyelination. **c)** Spectral Reflectance Confocal Microscopy (SCoRe) illustrating  
795 demyelination and IBA-1 macrophage activity in the corpus callosum resulting from 3 weeks of 0.2%  
796 cuprizone in normal chow. Error Bars 200  $\mu\text{m}$  except for the enlarged square where the Bar is 25  $\mu\text{m}$ .




799 **Supplementary Figure 6: Stereology, volume assessments and phenotypic staining**

800 **a)** Coronal section through a P60 mouse brain to illustrate how ROIs were captured for stereology.  
801 The cingulate bundles provided the anatomical landmark to limit the lateral margins of each trace,  
802 and the rostro-caudal margins were the midline unions of the corpus callosum: rostral, this was the  
803 most rostral aspect of the genu, and caudal, this was the most caudal aspect of the splenium. The  
804 white broken lines indicate a typical trace cortical and callosal trace. To the left of the image are  
805 collections of cortical and callosal traces from an individual at P60. The software used was  
806 stereoinvestigator V11 (MBF Bioscience). The dimensions for the bounding boxes surrounding the  
807 sets of traces are adjacent to the images. **b)** Total cortical volume increases significantly from P7 to  
808 P15. For all data: n=3–4 per age and the error bars represent  $\pm$  SD. **c)** Total callosal volume increased  
809 significantly from P5 to P365. **d)** Antibodies directed against Olig2, PDGFR $\alpha$  and CC1 were used to  
810 identify stages within the oligodendroglial lineage. Oligodendroglia were identified as any cell  
811 positive for Olig2. OPCs were identified as cells positive for Olig2 & PDGFR $\alpha$ . Oligodendrocytes are  
812 cells positive for Olig2 & CC1, and cells positive only for Olig2 were considered immature  
813 oligodendrocytes that had lost the expression of PDGFR $\alpha$ , but yet to express CC1. **e)** Graphical  
814 representation of the proportions of cells in the corpus callosum, and **F)** cortex. For all data: n=3–4  
815 per age; the error is  $\pm$  SD; and the statistics in all ANOVA with Tukey's post hoc testing significance is  
816 indicated: ns = no significance and stars; \*, \*\*, \*\*\*, \*\*\*\* represent  $p < 0.05$ ,  $p < 0.01$ , 0.001, and  
817  $p < 0.0001$ , respectively.

818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828






829  
830  
831

832 **Supplementary Figure 7: Change in total cell numbers in the corpus callosum**

833 **a)** Hoechst 33342 was used to identify the total number of nuclei in the tissue. **b)** Total numbers of  
 834 non-oligodendroglia (all cells positive for 33342 that lacked expression of the pan oligodendrocyte  
 835 marker Olig2). **c)** Total number of oligodendroglia (all cells positive for 33342 and Olig2). **d)** Total  
 836 number of oligodendrocytes (all cells positive for 3332, Olig2 and CC1). **e)** Total number of immature  
 837 oligodendrocytes (all cells positive for 33342 and Olig2 that lacked expression of CC1 and PDGFR $\alpha$ ).  
 838 **f)** Total number of OPCs (all cells positive for 33342, Olig2 and PDGFR $\alpha$ ). For all data: n=3–4 per age;  
 839 the error is  $\pm$  SD; and the statistics in all ANOVA with Tukey's post hoc testing significance is indicated:  
 840 ns = no significance and stars; \*, \*\*, \*\*\*, \*\*\*\* represent p<0.05, p<0.01, 0.001, and p<0.0001,  
 841 respectively.






842

843

844 **Supplementary Figure 8: Change in total cell numbers in the cortex**

845 **a)** Hoechst 33342 was used to identify the total number of nuclei in the tissue. **b)** Total numbers of  
 846 non-oligodendroglia (all cells positive for 33342 that lacked expression of the pan oligodendrocyte  
 847 marker Olig2). **c)** Total number of oligodendroglia (all cells positive for 33342 and Olig2). **d)** Total  
 848 number of oligodendrocytes (all cells positive for 3332, Olig2 and CC1). **e)** Total number of immature  
 849 oligodendrocytes (all cells positive for 33342 and Olig2 that lacked expression of CC1 and PDGFR $\alpha$ ).  
 850 **f)** Total number of OPCs (all cells positive for 33342, Olig2 and PDGFR $\alpha$ ). For all data: n=3–4 per age;  
 851 the error is  $\pm$  SD; and the statistics in all ANOVA with Tukey's post hoc testing significance is indicated:  
 852 ns = no significance and stars; \*, \*\*, \*\*\*, \*\*\*\* represent p<0.05, p<0.01, 0.001, and p<0.0001,  
 853 respectively.

854



856 **Supplementary Figure 9: Positive relationship between OPC density, production and GF**

857 **a)** Daily OPC production rates in the corpus callosum and cortex are strikingly distinct during  
 858 development and after 3 weeks of cuprizone induced demyelination (3W CPZ P70). For each data  
 859 point n= 3–5. Statistics: 2-way ANOVA analysis with multiple comparisons (black lines and stars), or  
 860 1-way ANOVA analysis (coloured lines and stars), significance: \*, \*\*, \*\*\*, \*\*\*\* = P<0.05, P<0.01,  
 861 0.001, and P<0.0001 respectively. Error bars = SD in all cases.

862 **b)** Gompertz logistic regression analysis revealed that OPC volumetric density is positively related to  
 863 their production rate (**also see Figure 1D**). A comparison of fits with the null hypothesis that one  
 864 curve fits all data points was not possible to reject P = 0.5305. The values for all equations are listed  
 865 below:

	$Y_M$	$Y_0$	$K$	$R^2$
<b>Corpus callosum</b>	19276	88.51	5.58E-05	0.973
<b>Cortex</b>	8143	37.54	9.41E-05	0.981
<b>Global (shared)</b>	19622	102.1	5.35E-05	0.977

866 It was possible to compare our results to Hughes et al<sup>13</sup>, who report that cortical OPCs at a density of  
 867 ~160 cells per 0.06mm<sup>3</sup> generate 0-7 cells per day (on average 3.5 cells per day)<sup>13</sup>. We converted  
 868 these values to mm<sup>3</sup> and the plotted the data (black hollow circle) which fell within the 95% CI for all  
 869 graphs (broken lines). Furthermore, if cortical OPCs are at a density of 160 cells per 0.06mm<sup>3</sup> (or 2667  
 870 mm<sup>3</sup>), our cortex relationship predicts the daily number of OPCs generated to be 7 cells (SD ± 7 cells)  
 871 per 0.06 mm<sup>3</sup> per day. In addition to this, we plotted data derived from animals fed 3 weeks of  
 872 cuprizone, this data point did not fall within the 95% CI intervals for any of the curves and indicates  
 873 that OPCs production to density relationship is lost during injury.

874 **c)** Padé (1,1) approximant (non-linear regression model) revealed OPC volumetric density is related  
 875 to their GF. A comparison of fits with the null hypothesis that one curve fits all data points was not  
 876 possible to reject P = 0.3715. The values are listed below:


	$A_0$	$A_1$	$B_1$	$R^2$
<b>Corpus callosum</b>	-0.6369	1.10E-04	2.40E-04	0.787
<b>Cortex</b>	-0.1081	3.35E-05	7.93E-05	0.607
<b>Global (shared)</b>	-0.1462	3.58E-05	6.98E-05	0.770

877 Using our data that OPC  $T_c$  is 35 h on average, along with the density and production rates identified  
 878 by Hughes et al<sup>13</sup>, it was possible to estimate a GF for their cortical OPCs (black hollow Square):

879 
$$GF = \frac{(OPC\ production \times T_c)}{(OPC\ density \times 24(h))} \rightarrow GF = 0.032$$

880 We plotted this GF value which fell very close to what was predicted by our cortical relationship. In  
 881 addition to this, we plotted data derived from animals fed 3 weeks of cuprizone. The relationship  
 882 between OPC production and density was strikingly distinct after injury. For each data point n= 3–5  
 883 and error bars = SD in all cases.

884



885


886

**Supplementary Figure 10: OL volumetric density in the corpus callosum and cortex**

887

**a)** Hoechst 33342 was used to identify the density (mm<sup>3</sup>) of nuclei in the tissue. **b)** Total number of non-oligodendroglia per mm<sup>3</sup> (all cells positive for 33342 that lacked expression of the pan oligodendrocyte marker Olig2). **c)** Total number of oligodendroglia per mm<sup>3</sup> (all cells positive for 33342 and Olig2). **d)** Total number of oligodendrocytes per mm<sup>3</sup> (all cells positive for 3332, Olig2 and CC1). **e)** Total number of immature oligodendrocytes per mm<sup>3</sup> (all cells positive for 33342 and Olig2 that lacked expression of CC1 and PDGFRα). **f)** Total number of OPCs per mm<sup>3</sup> (all cells positive for 33342, Olig2 and PDGFRα). For all data: n=3–4 per; the error is ± SD; and the statistics in all figures 2-way ANOVA testing (Indicated by black broken line) and ANOVA with Tukey's post hoc multiple comparisons (Coloured lines). Significance is indicated, ns = no significance and stars; \*, \*\*, \*\*\*, \*\*\*\* represents p<0.05, p<0.01, 0.001, and p<0.0001 respectively.



897



898  
899

900 **Supplementary Figure 11: Age-related increase in myelin in the corpus callosum**

901 SCoRe imaging of compact myelin in the corpus callosum, demonstrating an age-related increase in  
 902 callosal area positive for SCoRE signal. Care was taken to ensure the coronal sections compared were  
 903 from same relative anatomical position cutting from the Splenium of the corpus callosum forward.  
 904 Large image bar = 200  $\mu$ m, excerpt enlarged image bar = 20  $\mu$ m.




906 **Supplementary Figure 12: Identification and quantification of the % of pyknotic nuclei**

907 **a)** Pyknotic nuclei were identified using Hoechst 33342<sup>31</sup>. Two ROIs are shown enlarged to show the  
908 pyknotic profile (the square without an asterisk) and the dividing nuclear profile (the square with an  
909 asterisk). Arrow heads indicate a pyknotic cell and paired arrows indicate the equatorial plane of a  
910 dividing OPC (positive for PDGFR $\alpha$  and Olig2). Bar 200  $\mu$ m and 10  $\mu$ m. **b)** The % of all pyknotic nuclei  
911 in the corpus callosum and cortex respectively, as well as the fraction of pyknotic nuclei identified by  
912 Barres et al (1992) in the developing Optic Nerve<sup>35</sup>. Error bars  $\pm$  SD. Statistics are from cell counts,  
913 n=3–4 for each data point, a 2-way ANOVA testing data from the corpus callosum and cortex, the  
914 significant interaction is indicated by stars\*\*\*\* = p<0.001.

915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925





926  
927  
928  
929

930 **Supplementary Figure 13: Sensitivity analysis: systematically varying Tc or GF dramatically alters**  
931 **cumulative production**

932 To provide additional validation that OPCs Tc is stable over the long term, we modelled cumulative  
933 production in the corpus callosum using a fixed OPC Tc of 35 hours. This produced a similar curve  
934 (broken green line) to what was generated when the measured cell cycle values were used (solid  
935 black line). To illustrate how total cumulative production changes if GF, or Tc, values were  
936 systematically over or underestimated, we again modelled cumulative production with systematic  
937 alterations to only the GF or the Tc by: 1) a value equal to  $\pm$  the standard deviation of the measured  
938 average value at each time point, or 2):  $\pm$  50% of the average measured value at each time point.  
939 Overlaid on the graph is the change in total OL number as determined by stereology (black circles). n  
940 = 3–4 for each measured data point and the error bars =  $\pm$  SD.

941 **Full Reference List:**

- 942 1. Gibson, E.M., *et al.* Neuronal activity promotes oligodendrogenesis and adaptive myelination  
943 in the mammalian brain. *Science* **344**, 1252304 (2014).
- 944 2. Yeung, M.S.Y., *et al.* Dynamics of Oligodendrocyte Generation and Myelination in the Human  
945 Brain. *Cell* **159**, 766-774 (2014).
- 946 3. Nowakowski, R.S., Lewin, S.B. & Miller, M.W. Bromodeoxyuridine immunohistochemical  
947 determination of the lengths of the cell cycle and the DNA-synthetic phase for an anatomically  
948 defined population. *J Neurocytol* **18**, 311-318 (1989).
- 949 4. van Heyningen, P., Calver, A.R. & Richardson, W.D. Control of progenitor cell number by  
950 mitogen supply and demand. *Curr Biol* **11**, 232-241 (2001).
- 951 5. Psachoulia, K., Jamen, F., Young, K.M. & Richardson, W.D. Cell cycle dynamics of NG2 cells in  
952 the postnatal and ageing brain. *Neuron Glia Biol* **5**, 57-67 (2009).
- 953 6. Simon, C., Gotz, M. & Dimou, L. Progenitors in the Adult Cerebral Cortex: Cell Cycle Properties  
954 and Regulation by Physiological Stimuli and Injury. *Glia* **59**, 869-881 (2011).
- 955 7. Clarke, L.E., *et al.* Properties and fate of oligodendrocyte progenitor cells in the corpus  
956 callosum, motor cortex, and piriform cortex of the mouse. *J Neurosci* **32**, 8173-8185 (2012).
- 957 8. Young, K.M., *et al.* Oligodendrocyte dynamics in the healthy adult CNS: evidence for myelin  
958 remodeling. *Neuron* **77**, 873-885 (2013).
- 959 9. Rivers, L.E., *et al.* PDGFRA/NG2 glia generate myelinating oligodendrocytes and piriform  
960 projection neurons in adult mice. *Nat Neurosci* **11**, 1392-1401 (2008).
- 961 10. Gonsalvez, D.G., *et al.* Proliferation and cell cycle dynamics in the developing stellate ganglion.  
962 *J Neurosci* **33**, 5969-5979 (2013).
- 963 11. Gao, F.B., Durand, B. & Raff, M. Oligodendrocyte precursor cells count time but not cell  
964 divisions before differentiation. *Curr Biol* **7**, 152-155 (1997).
- 965 12. Marques, S., *et al.* Oligodendrocyte heterogeneity in the mouse juvenile and adult central  
966 nervous system. *Science* **352**, 1326-1329 (2016).
- 967 13. Hughes, E.G., Kang, S.H., Fukaya, M. & Bergles, D.E. Oligodendrocyte progenitors balance  
968 growth with self-repulsion to achieve homeostasis in the adult brain. *Nat Neurosci* **16**, 668-  
969 676 (2013).
- 970 14. Hughes, E.G., Orthmann-Murphy, J.L., Langseth, A.J. & Bergles, D.E. Myelin remodeling  
971 through experience-dependent oligodendrogenesis in the adult somatosensory cortex. *Nat*  
972 *Neurosci* **21**, 696-706 (2018).
- 973 15. Hill, R.A., Li, A.M. & Grutzendler, J. Lifelong cortical myelin plasticity and age-related  
974 degeneration in the live mammalian brain. *Nature Neuroscience* **21**, 683-+ (2018).
- 975 16. Sturrock, R.R. Myelination of the mouse corpus callosum. *Neuropathol Appl Neurobiol* **6**, 415-  
976 420 (1980).
- 977 17. Tripathi, R.B., *et al.* Remarkable Stability of Myelinating Oligodendrocytes in Mice. *Cell Rep*  
978 **21**, 316-323 (2017).
- 979 18. Sun, L.O., *et al.* Spatiotemporal Control of CNS Myelination by Oligodendrocyte Programmed  
980 Cell Death through the TFEB-PUMA Axis. *Cell* **175**, 1811-1826 e1821 (2018).
- 981 19. Thomaidou, D., Mione, M.C., Cavanagh, J.F.R. & Parnavelas, J.G. Apoptosis and its relation to  
982 the cell cycle in the developing cerebral cortex. *Journal of Neuroscience* **17**, 1075-1085 (1997).
- 983 20. Mitew, S., *et al.* Pharmacogenetic stimulation of neuronal activity increases myelination in an  
984 axon-specific manner. *Nat Commun* **9**, 306 (2018).
- 985 21. Xiao, L., *et al.* Rapid production of new oligodendrocytes is required in the earliest stages of  
986 motor-skill learning. *Nature Neuroscience* **19**, 1210-1217 (2016).

- 987 22. Hayes, N.L. & Nowakowski, R.S. Exploiting the dynamics of S-phase tracers in developing  
988 brain: Interkinetic nuclear migration for cells entering versus leaving the S-phase. *Dev*  
989 *Neurosci-Basel* **22**, 44-55 (2000).
- 990 23. Basak, O., *et al.* Mapping early fate determination in Lgr5(+) crypt stem cells using a novel  
991 Ki67-RFP allele. *Embo Journal* **33**, 2057-2068 (2014).
- 992 24. Gerdes, J., *et al.* Cell cycle analysis of a cell proliferation-associated human nuclear antigen  
993 defined by the monoclonal antibody Ki-67. *J Immunol* **133**, 1710-1715 (1984).
- 994 25. Miller, I., *et al.* Ki67 is a Graded Rather than a Binary Marker of Proliferation versus  
995 Quiescence. *Cell Reports* **24**, 1105-+ (2018).
- 996 26. Heidebrecht, H.J., Buck, F., Haas, K., Wacker, H.H. & Parwaresch, R. Monoclonal antibodies Ki-  
997 S3 and Ki-S5 yield new data on the 'Ki-67' proteins. *Cell Proliferat* **29**, 413-425 (1996).
- 998 27. Rungta, R.L., Chaigneau, E., Osmanski, B.F. & Charpak, S. Vascular Compartmentalization of  
999 Functional Hyperemia from the Synapse to the Pia. *Neuron* **99**, 362-+ (2018).
- 000 28. Gonsalvez, D.G., *et al.* Imaging and Quantification of Myelin Integrity After Injury With  
001 Spectral Confocal Reflectance Microscopy. *Front Mol Neurosci* **12**, 275 (2019).
- 002 29. Govier-Cole, A.E., *et al.* Inhibiting Bone Morphogenetic Protein 4 Type I Receptor Signaling  
003 Promotes Remyelination by Potentiating Oligodendrocyte Differentiation. *eNeuro* **6** (2019).
- 004 30. Kazanis, I., *et al.* Subependymal Zone-Derived Oligodendroblasts Respond to Focal  
005 Demyelination but Fail to Generate Myelin in Young and Aged Mice. *Stem Cell Rep* **8**, 685-700  
006 (2017).
- 007 31. Crowley, L.C., Marfell, B.J. & Waterhouse, N.J. Analyzing Cell Death by Nuclear Staining with  
008 Hoechst 33342. *Cold Spring Harb Protoc* **2016** (2016).
- 009 32. Bursch, W., Kleine, L. & Tenniswood, M. The Biochemistry of Cell-Death by Apoptosis.  
010 *Biochem Cell Biol* **68**, 1071-1074 (1990).
- 011 33. Green, D.R. Apoptotic pathways: Ten minutes to dead. *Cell* **121**, 671-674 (2005).
- 012 34. Hill, R.A., Patel, K.D., Goncalves, C.M., Grutzendler, J. & Nishiyama, A. Modulation of  
013 oligodendrocyte generation during a critical temporal window after NG2 cell division. *Nat*  
014 *Neurosci* **17**, 1518-1527 (2014).
- 015 35. Barres, B.A., *et al.* Cell-Death and Control of Cell-Survival in the Oligodendrocyte Lineage. *Cell*  
016 **70**, 31-46 (1992).
- 017

## 018 **Acknowledgements:**

019 All images were collected at the Biological Optical Platform at the University of Melbourne, and the  
020 Florey Advanced Microscopy and Immunohistochemistry Service. In particular we would like to  
021 acknowledge Dr Carolina Chavez (FAMIS) for her help with stereoinvestigator; Dr Jessica L Fletcher  
022 and Dr David Homewood (Dept. Anatomy and Neuroscience University of Melbourne) for ongoing  
023 comments and input over the course of the project. This project was funded by: National Health  
024 and Medical Research Council (NHMRC) Early Career Fellowship (#GNT1111041 to DGG), Multiple  
025 Sclerosis Research Australia Betty Cuthbert Fellowship (#15-059 to DGG), NHMRC Project Grant  
026 (#GNT1058647 to JX), Australian research Council (ARC) Discovery Project Grant (#DP180102397 to  
027 JX) and ARC Discovery Project (#DP140100339 to BDH).

028

029